<DOC>
	<DOCNO>NCT01060579</DOCNO>
	<brief_summary>A 28 day study safety efficacy two concentration topical AR-12286 treating ocular hypertension open-angle glaucoma compare latanoprost . Hypothesis : The ocular hypotensive efficacy dose AR-12286 ophthalmic solution different active control .</brief_summary>
	<brief_title>Study AR-12286 Versus Latanoprost Patients With Elevated Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) currently treat ocular hypotensive medication . 3 . Unmedicated ( postwashout ) IOP ≥ 22 mm Hg 2 eligibility visit ( 07:0009:00 hr ) , 27 day apart . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Has use commercially available IOPlowering medication one eye least 30 day 90 day prior screen visit . 6 . Able willing give sign informed consent follow study instruction . Ophthalmic ( either eye ) : 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure . Note : Previous laser peripheral iridotomy acceptable . 2 . Intraocular pressure &gt; 36 mm Hg 3 . Known hypersensitivity component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . 4 . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . 5 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . 6 . Ocular trauma within past six month , ocular surgery laser treatment within past three month . 7 . History evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) , herpes simplex keratitis 8 . Contact lens wear within 30 minute instillation study medication . 9 . Ocular medication kind within 30 day Visit 1 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 1 ) c ) lubricate drop dry eye ( may use throughout study ) . 10 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( i.e. , cupdisc ratio &gt; 0.8 ) . 11 . Central corneal thickness great 600 μ . 12 . Any abnormality prevent reliable applanation tonometry either eye . Systemic : 1 . Clinically significant abnormality laboratory test screen . 2 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 3 . Participation investigational study within past 30 day . 4 . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . 5 . Due status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>